Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Elanco Animal Health executive Rajeev A. Modi reported a routine equity award. On February 6, 2026, he acquired 56.1357 deferred stock units at a reference price of $25.2 per unit. Following this transaction, he beneficially owned 7,594.4613 deferred stock units, held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
FMR LLC has filed an amended Schedule 13G indicating beneficial ownership of 52,196,321.38 shares of Elanco Animal Health Inc. common stock, representing 10.5% of the class. FMR reports sole voting power over 44,813,598.91 shares and sole dispositive power over 52,196,321.38 shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 52,196,321.38 shares and no voting power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Elanco.
Elanco Animal Health’s president and CEO Jeffrey N. Simmons reported an acquisition of derivative equity compensation. On January 23, 2026, he received 113.4934 deferred stock units at a reference price of $24.4 per unit, increasing his holdings to 18,959.0151 deferred stock units.
Each deferred stock unit gives the right to receive either one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi reported a routine equity compensation transaction. On 01/23/2026, he was awarded 57.9762 deferred stock units at a reference price of $24.4 per unit, increasing his beneficial holdings of these units to 7,538.3256, held directly.
The deferred stock units each represent the right to receive either one share of Elanco common stock or the cash equivalent. They will settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported an acquisition of derivative securities. On January 23, 2026, he acquired 7.8029 deferred stock units at a reference price of $24.4 per unit.
Following this transaction, he beneficially owned 15.915 deferred stock units directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Dimensional Fund Advisors LP filed a Schedule 13G reporting a passive ownership stake in Elanco Animal Health Inc. common stock. As of 12/31/2025, Dimensional is deemed to beneficially own 25,082,545 shares, representing 5.0% of Elanco’s common stock. The firm has sole voting power over 24,595,193 shares and sole dispositive power over 25,082,545 shares.
The shares are actually owned by various funds and accounts advised or sub-advised by Dimensional. Dimensional states that it may be deemed a beneficial owner only for Section 13(d) purposes and expressly disclaims beneficial ownership. The position is certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Elanco.
Elanco Animal Health executive Rajeev A. Modi reported an award of deferred stock units. On 01/09/2026, he acquired 60.2735 deferred stock units at a value of $23.47 per unit, classified as a derivative security and held directly.
Following this transaction, Modi beneficially owned a total of 7,480.3494 deferred stock units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported a small compensation-related equity transaction. On 01/09/2026 he acquired 8.1121 deferred stock units at a reference price of $23.47 per unit, as disclosed on a Form 4.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and the units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan. After this transaction, he beneficially owns 8.1121 deferred stock units directly.
Elanco Animal Health Inc. CEO Jeffrey N. Simmons, who also serves as president and director, reported an acquisition of deferred stock units under a company plan. On January 9, 2026, he was credited with 117.9906 deferred stock units at a reference price of $23.47 per unit, bringing his total holdings to 18,845.5217 deferred stock units.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are designed to settle in cash or shares after employment ends or in a specified future year, in line with the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Incorporated filed a report stating that on January 13, 2026, it will present at the 44th Annual J.P. Morgan Healthcare Conference. The company has prepared an investor presentation for this event, which is included as Exhibit 99.1. This presentation is being made available as supplemental information for investors and analysts.
The disclosure is furnished under a provision that means it is not considered “filed” for liability purposes under the Securities Exchange Act and will only be incorporated into other documents if expressly stated. No financial results, transactions, or strategic changes are described in this report beyond the announcement of the conference presentation.